Recent studies suggest that targeted inhibition of the EGFR pathway using small-molecule EGFR inhibitors may offer a new systemic treatment option for MEC patients with CRTC1-MAML2 translocations (15). Here, EGFR is linked to mucoepidermoid carcinoma.